However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 20245 investor ...

Novo Nordisk's share price has taken a battering over the past year amid increased competition in the ballooning obesity drug ...

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

A key reason for NVO's drop is the disappointing trial results for its obesity and diabetes treatment CagriSema. The first big price fall came after the company released its phase 3 trial results ...

However, the company has struggled to shake negative sentiment following a series of disappointing trial results for its next-generation obesity drug candidate CagriSema. Novo Nordisk confirmed ...